Marcio Souza - 18 Jun 2021 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (SYRE)

Role
Director
Signature
/s/ Steven Weber, by power of attorney
Issuer symbol
SYRE
Transactions as of
18 Jun 2021
Net transactions value
$0
Form type
4
Filing time
22 Jun 2021, 16:07:02 UTC
Next filing
19 Aug 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGLE Director Stock Option (right to buy) Award $0 +60,000 $0.000000 60,000 18 Jun 2021 Common Stock 60,000 $6.44 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests and becomes exercisable in 36 equal monthly installments beginning on July 18, 2021 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.